Streetbeat News

Stock Prices

SUPN

Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 earnings with an EPS of $0.39, missing estimates by -29% and a revenue decrease of $3.01 million from the previous year. Despite missing last quarter's EPS estimate, the share price increased by 11% the following day. The company's past earnings performance shows mixed results with both misses and beats on EPS and revenue estimates.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 9:30 pm

KURA

Kura Oncology (NASDAQ:KURA) reported its Q4 earnings on February 27, 2024, with an EPS of $-0.55, matching the estimated earnings. The revenue remained unchanged from the same period last year. In the previous quarter, KURA beat the EPS estimate by $0.05, leading to a 7% increase in its share price the following day.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 9:30 pm

FDS

FactSet Research Systems (NYSE:FDS) has delivered an average annual return of 18.31% over the past 15 years, outperforming the market by 4.38% annually. A $100 investment in FDS 15 years ago would be worth $1,273.92 today. The company currently has a market capitalization of $17.58 billion.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 9:30 pm

FLYW

Flywire (NASDAQ:FLYW) reported Q4 earnings with an EPS of $0.01, surpassing the estimated -$0.07 by 114%. Revenue increased by $27.49 million year-over-year. Despite missing EPS estimates last quarter leading to a 25% share price drop, this quarter's performance marks a significant improvement.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 9:30 pm

AVGO

Broadcom (NASDAQ:AVGO) has significantly outperformed the market over the past 5 years, with an annualized return of 36.37%, turning a $100 investment into $475.24 today. The company's market capitalization stands at $606.82 billion.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 9:30 pm

OSUR

OraSure Technologies (NASDAQ:OSUR) reported Q4 earnings with an EPS of $0.22, beating estimates by 175% but with a revenue decrease of $47.20 million from the previous year. The company has a history of surpassing EPS estimates, leading to share price increases.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 9:30 pm

PRCT

PROCEPT BioRobotics (NASDAQ:PRCT) reported Q4 earnings with a -23.0% miss on estimated EPS, recording -$0.54 versus the -$0.44 estimate. Revenue increased by $19.80 million year-over-year. Despite the miss, past performance shows a positive trend in share price following earnings reports.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 9:30 pm

CARA

GENE

IIPR

NEPT

SMG

TLRY

The cannabis sector experienced significant movement on February 27, 2024, with a majority of stocks showing bullish sentiment. Notable gainers include GreenGro Technologies with a 9900.00% increase and Elixinol Wellness up by 75.56%. On the downside, Australis Capital plummeted by 99.00%, and AusCann Group Holdings fell by 83.95%. This movement reflects a volatile but predominantly positive day for cannabis-related stocks.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 9:30 pm

SUPN

Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 2023 adjusted EPS of $0.39, missing the $0.55 estimate, but sales of $164.31M exceeded the $155.03M estimate, a 1.80% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 9:30 pm

AAPL

AMZN

GOOGL

LYV

UNH

The Justice Department has initiated an antitrust investigation into UnitedHealth Group Inc. (NYSE:UNH), focusing on its competitive practices within the healthcare sector. This investigation is part of a broader effort by the Biden administration to increase antitrust scrutiny across major sectors, including technology and healthcare. The probe specifically examines the relationship between UnitedHealthcare and Optum, amid concerns over UnitedHealth's acquisition strategies and their impact on competition and consumers. UnitedHealth Group's shares fell by 2.27% following the news.

Portfolio Pulse from Piero Cingari

February 27, 2024 | 9:28 pm